Tanya Quinn

Former Senior Director-Global Distribution at The Medicines Co.

Tanya Quinn

Tanya Quinn

Former Senior Director-Global Distribution at The Medicines Co.

Biography

Tanya Quinn is former Senior Director-Global Distribution at The Medicines Co.

Overview
RelSci Relationships

136

Relationships
RelSci Relationships are individuals Tanya Quinn likely has professional access to. A relationship does not necessarily indicate a personal connection.

Head, Global Communications at The Medicines Co.

Relationship likelihood: Average

Executive Vice President, General Counsel & Secretary at The Medicines Co.

Relationship likelihood: Average

Global Launch Leader, Anti-Platelet Solutions at The Medicines Co.

Relationship likelihood: Average

Chief Financial Officer & Treasurer at The Medicines Co.

Relationship likelihood: Average

Head, Global Contracting & Business Ethics at The Medicines Co.

Relationship likelihood: Average

Chief Executive Officer at Rempex Pharmaceuticals, Inc.

Relationship likelihood: Average

President, Chief Executive Officer & Director at Ophthotech Corp.

Relationship likelihood: Average

Chief Financial Officer & Treasurer at Ophthotech Corp.

Relationship likelihood: Average

Executive Vice President at The Medicines Co.

Relationship likelihood: Average

Co-Founder at The Medicines Co.

Relationship likelihood: Average

Paths to Tanya Quinn
Potential Connections via
Relationship Science
You
Tanya Quinn
Former Senior Director-Global Distribution at The Medicines Co.
Career History
Senior Director-Global Distribution
Prior - 2016

The Medicines Co We are a global pharmaceutical company focused on advancing the treatment of critical care patients through the delivery of innovative, cost-effective medicines to the worldwide hospital marketplace. In the United States, we have three marketed products, Angiomax® (bivalirudin) for Injection, Cleviprex® (clevidipine) Injectable Emulsion, and Argatroban Injection, 50 mg per 50 mL†. We also have a pipeline of acute and intensive care hospital products in development, including three late-stage development product candidates, cangrelor, oritavancin and MDCO-157, and two early stage development product candidates, MDCO-2010 and MDCO-216. We believe that Angiomax, Cleviprex and our products in development possess favorable attributes that can satisfy unmet medical needs in the acute | intensive care hospital product market and offer, or, in the case of our products in development, have the potential to offer, improved performance to hospital businesses. The Company is publicly traded on the Nasdaq exchange under the ticker symbol MDCO. It was founded in 1996 and employs approximately 425 professionals.

Other Affiliations

Tanya Quinn is affiliated with The Medicines Co.

This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Tanya Quinn. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Tanya Quinn's profile does not indicate a business or promotional relationship of any kind between RelSci and Tanya Quinn.